CTOs on the Move

Eton Pharmaceuticals

www.etonpharma.com

 
Eton is an innovative pharmaceutical company that searches the world over for meaningful therapies that we can bring to patients living with rare diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

SBH Willow Peak

Willow Creek Behavioral Health provides mental health treatment and group therapy in Green Bay, WI. Our hospital provides innovative treatments and 24/7 access to care.

Amryt Pharma

We are a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments that help improve the lives of people with rare and orphan diseases.

Indegene

We are a technology-led healthcare solutions provider. We combine deep industry expertise with fit-for-purpose technology in an agile and scalable operating model. Many of the leading, global healthcare organizations rely on us to deliver effective and efficient clinical, medical, and commercial outcomes every day. From strategy to execution, we enable healthcare organizations be future ready.

Y's Therapeutics

Y's Therapeutics, Inc is a San Bruno, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Milestone Pharmaceuticals

Milestone was founded in 2005 with the underlying concept to base its drug development programs on clinically validated mechanisms of action in order to mitigate as much drug development risk as possible. The company has raised a total of $34 million in venture capital financing since 2006. At its founding, the company assembled a panel of leading pharmaceutical R&D executives (“drug hunters”) each with an average of 30 years experience in drug development. The drug hunters proposed NCE projects based on clinically proven science to form the basis of Milestone’s drug development programs. Milestone has a seasoned management team with experience in cardiovascular diseases, drug development and business start-ups as well as world-class advisory boards of key opinion leaders with significant expertise in cardiology, regulatory affairs, as well as formulation and drug development.